BACKGROUND: Prognosis of patients with heart failure (HF) has improved in recent years due to advances in therapy. Whether this is also true for diabetic subjects with HF in clinical practice has not been studied in a prospective manner. METHODS: All patients with HF and left ventricular systolic dysfunction attending the outpatient clinic at our Veteran's Hospital between October 1999 and November 2000 were enrolled in our study and followed prospectively. Electronic medical records were accessed for data on comorbid conditions, medications, echocardiogram results and mortality information. Mean follow-up was 2.7 years. RESULTS: Of 495 patients with HF due to systolic dysfunction enrolled in the study, 293 (59%) had diabetes. Prevalence of hypertension, diuretic use and angiotensin converting enzyme inhibitor use was higher among diabetics. Beta-blocker usage was equal and high in both groups (60%). On follow-up, 109/273 (37%) patients in the diabetic group died, compared with 49/202 (24%) in the non-diabetic group. Independent predictors of death were diabetes (p<0.005, OR=1.73), age at enrollment (p<0.0001, OR=1.06), serum creatinine (p<0.01, OR=1.44) and diuretic use (p=0.038, OR=1.85). Beta-blocker use was associated with a decreased risk of death on univariate analysis only. CONCLUSIONS: Our results show that diabetic patients with HF continue to have higher mortality than non-diabetic patients with HF despite advances in therapy.
BACKGROUND: Prognosis of patients with heart failure (HF) has improved in recent years due to advances in therapy. Whether this is also true for diabetic subjects with HF in clinical practice has not been studied in a prospective manner. METHODS: All patients with HF and left ventricular systolic dysfunction attending the outpatient clinic at our Veteran's Hospital between October 1999 and November 2000 were enrolled in our study and followed prospectively. Electronic medical records were accessed for data on comorbid conditions, medications, echocardiogram results and mortality information. Mean follow-up was 2.7 years. RESULTS: Of 495 patients with HF due to systolic dysfunction enrolled in the study, 293 (59%) had diabetes. Prevalence of hypertension, diuretic use and angiotensin converting enzyme inhibitor use was higher among diabetics. Beta-blocker usage was equal and high in both groups (60%). On follow-up, 109/273 (37%) patients in the diabetic group died, compared with 49/202 (24%) in the non-diabetic group. Independent predictors of death were diabetes (p<0.005, OR=1.73), age at enrollment (p<0.0001, OR=1.06), serum creatinine (p<0.01, OR=1.44) and diuretic use (p=0.038, OR=1.85). Beta-blocker use was associated with a decreased risk of death on univariate analysis only. CONCLUSIONS: Our results show that diabeticpatients with HF continue to have higher mortality than non-diabeticpatients with HF despite advances in therapy.
Authors: Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman Journal: Am J Kidney Dis Date: 2009-12-30 Impact factor: 8.860
Authors: Nathaniel Mark Hawkins; Mark C Petrie; Pardeep S Jhund; George W Chalmers; Francis G Dunn; John J V McMurray Journal: Eur J Heart Fail Date: 2009-02 Impact factor: 15.534
Authors: Britt Falskov; Thomas Steffen Hermann; Christian Rask-Madsen; Atheline Major-Pedersen; Buris Christiansen; Jakob Raunsø; Lars Køber; Christian Torp-Pedersen; Helena Dominguez Journal: Vasc Health Risk Manag Date: 2011-12-19
Authors: Lorenzo Conte; Iacopo Fabiani; Valentina Barletta; Cristina Bianchi; Ciccarone Anna Maria; Cuono Cucco; Marianna De Filippi; Roberto Miccoli; Stefano Del Prato; Carlo Palombo; Vitantonio Di Bello Journal: J Cardiovasc Echogr Date: 2013 Jul-Sep